Cargando…
The spleen may be an important target of stem cell therapy for stroke
Stroke is the most common cerebrovascular disease, the second leading cause of death behind heart disease and is a major cause of long-term disability worldwide. Currently, systemic immunomodulatory therapy based on intravenous cells is attracting attention. The immune response to acute stroke is a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352449/ https://www.ncbi.nlm.nih.gov/pubmed/30700305 http://dx.doi.org/10.1186/s12974-019-1400-0 |
_version_ | 1783390843670888448 |
---|---|
author | Wang, Zhe He, Da Zeng, Ya-Yue Zhu, Li Yang, Chao Lu, Yong-Juan Huang, Jie-Qiong Cheng, Xiao-Yan Huang, Xiang-Hong Tan, Xiao-Jun |
author_facet | Wang, Zhe He, Da Zeng, Ya-Yue Zhu, Li Yang, Chao Lu, Yong-Juan Huang, Jie-Qiong Cheng, Xiao-Yan Huang, Xiang-Hong Tan, Xiao-Jun |
author_sort | Wang, Zhe |
collection | PubMed |
description | Stroke is the most common cerebrovascular disease, the second leading cause of death behind heart disease and is a major cause of long-term disability worldwide. Currently, systemic immunomodulatory therapy based on intravenous cells is attracting attention. The immune response to acute stroke is a major factor in cerebral ischaemia (CI) pathobiology and outcomes. Over the past decade, the significant contribution of the spleen to ischaemic stroke has gained considerable attention in stroke research. The changes in the spleen after stroke are mainly reflected in morphology, immune cells and cytokines, and these changes are closely related to the stroke outcomes. Autonomic nervous system (ANS) activation, release of central nervous system (CNS) antigens and chemokine/chemokine receptor interactions have been documented to be essential for efficient brain-spleen cross-talk after stroke. In various experimental models, human umbilical cord blood cells (hUCBs), haematopoietic stem cells (HSCs), bone marrow stem cells (BMSCs), human amnion epithelial cells (hAECs), neural stem cells (NSCs) and multipotent adult progenitor cells (MAPCs) have been shown to reduce the neurological damage caused by stroke. The different effects of these cell types on the interleukin (IL)-10, interferon (IFN), and cholinergic anti-inflammatory pathways in the spleen after stroke may promote the development of new cell therapy targets and strategies. The spleen will become a potential target of various stem cell therapies for stroke represented by MAPC treatment. |
format | Online Article Text |
id | pubmed-6352449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63524492019-02-06 The spleen may be an important target of stem cell therapy for stroke Wang, Zhe He, Da Zeng, Ya-Yue Zhu, Li Yang, Chao Lu, Yong-Juan Huang, Jie-Qiong Cheng, Xiao-Yan Huang, Xiang-Hong Tan, Xiao-Jun J Neuroinflammation Review Stroke is the most common cerebrovascular disease, the second leading cause of death behind heart disease and is a major cause of long-term disability worldwide. Currently, systemic immunomodulatory therapy based on intravenous cells is attracting attention. The immune response to acute stroke is a major factor in cerebral ischaemia (CI) pathobiology and outcomes. Over the past decade, the significant contribution of the spleen to ischaemic stroke has gained considerable attention in stroke research. The changes in the spleen after stroke are mainly reflected in morphology, immune cells and cytokines, and these changes are closely related to the stroke outcomes. Autonomic nervous system (ANS) activation, release of central nervous system (CNS) antigens and chemokine/chemokine receptor interactions have been documented to be essential for efficient brain-spleen cross-talk after stroke. In various experimental models, human umbilical cord blood cells (hUCBs), haematopoietic stem cells (HSCs), bone marrow stem cells (BMSCs), human amnion epithelial cells (hAECs), neural stem cells (NSCs) and multipotent adult progenitor cells (MAPCs) have been shown to reduce the neurological damage caused by stroke. The different effects of these cell types on the interleukin (IL)-10, interferon (IFN), and cholinergic anti-inflammatory pathways in the spleen after stroke may promote the development of new cell therapy targets and strategies. The spleen will become a potential target of various stem cell therapies for stroke represented by MAPC treatment. BioMed Central 2019-01-30 /pmc/articles/PMC6352449/ /pubmed/30700305 http://dx.doi.org/10.1186/s12974-019-1400-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Wang, Zhe He, Da Zeng, Ya-Yue Zhu, Li Yang, Chao Lu, Yong-Juan Huang, Jie-Qiong Cheng, Xiao-Yan Huang, Xiang-Hong Tan, Xiao-Jun The spleen may be an important target of stem cell therapy for stroke |
title | The spleen may be an important target of stem cell therapy for stroke |
title_full | The spleen may be an important target of stem cell therapy for stroke |
title_fullStr | The spleen may be an important target of stem cell therapy for stroke |
title_full_unstemmed | The spleen may be an important target of stem cell therapy for stroke |
title_short | The spleen may be an important target of stem cell therapy for stroke |
title_sort | spleen may be an important target of stem cell therapy for stroke |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352449/ https://www.ncbi.nlm.nih.gov/pubmed/30700305 http://dx.doi.org/10.1186/s12974-019-1400-0 |
work_keys_str_mv | AT wangzhe thespleenmaybeanimportanttargetofstemcelltherapyforstroke AT heda thespleenmaybeanimportanttargetofstemcelltherapyforstroke AT zengyayue thespleenmaybeanimportanttargetofstemcelltherapyforstroke AT zhuli thespleenmaybeanimportanttargetofstemcelltherapyforstroke AT yangchao thespleenmaybeanimportanttargetofstemcelltherapyforstroke AT luyongjuan thespleenmaybeanimportanttargetofstemcelltherapyforstroke AT huangjieqiong thespleenmaybeanimportanttargetofstemcelltherapyforstroke AT chengxiaoyan thespleenmaybeanimportanttargetofstemcelltherapyforstroke AT huangxianghong thespleenmaybeanimportanttargetofstemcelltherapyforstroke AT tanxiaojun thespleenmaybeanimportanttargetofstemcelltherapyforstroke AT wangzhe spleenmaybeanimportanttargetofstemcelltherapyforstroke AT heda spleenmaybeanimportanttargetofstemcelltherapyforstroke AT zengyayue spleenmaybeanimportanttargetofstemcelltherapyforstroke AT zhuli spleenmaybeanimportanttargetofstemcelltherapyforstroke AT yangchao spleenmaybeanimportanttargetofstemcelltherapyforstroke AT luyongjuan spleenmaybeanimportanttargetofstemcelltherapyforstroke AT huangjieqiong spleenmaybeanimportanttargetofstemcelltherapyforstroke AT chengxiaoyan spleenmaybeanimportanttargetofstemcelltherapyforstroke AT huangxianghong spleenmaybeanimportanttargetofstemcelltherapyforstroke AT tanxiaojun spleenmaybeanimportanttargetofstemcelltherapyforstroke |